WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201686

CAS#: 897016-82-9 (free base)

Description: KX2-391, also known as KXO1, is an orally bioavailable small molecule Src kinase inhibitor with potential antineoplastic activity. Unlike other Src kinase inhibitors which bind to the ATP-binding site, Src kinase inhibitor KX2-391 specifically binds to the peptide substrate binding site of Src kinase; inhibition of kinase activity may result in the inhibition of primary tumor growth and the suppression of metastasis. Src tyrosine kinases are upregulated in many tumor cells and play important roles in tumor cell proliferation and metastasis.

Price and Availability


USD 265

USD 485

USD 950

KX2-391, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 201686
Name: KX2-391
CAS#: 897016-82-9 (free base)
Chemical Formula: C26H29N3O3
Exact Mass: 431.22089
Molecular Weight: 431.53
Elemental Analysis: C, 72.37; H, 6.77; N, 9.74; O, 11.12

Related CAS #: 897016-82-9 (free base)   1038395-65-1 (HCl)  

Synonym: KX01, KX-01, KX 01; KX2391, KX-2391, KX 2391

IUPAC/Chemical Name: (E)-(4-(2-(1H-indazol-3-yl)vinyl)phenyl)(piperazin-1-yl)methanone


InChi Code: InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10,21H,11-14H2,(H,22,23)/b10-7+


Technical Data

Solid powder


Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



 1. Hangauer, David G.; Smolinski, Michael; Bu, Yahao; Kazim, Latif; Qu, Jun. Photoaffinity labeling studies to better define the mechanism of action for Phase II oncology drug KX2-391. Abstracts of Papers, 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, 2010 (2010), MEDI-295. CODEN: 69MML8 AN 2010:344831

2. Hangauer, David G., Jr.; Patra, Debasis; Cody, Jeremy A.; Palmer, Grant J.; Isbester, Paul K.; Salsbury, Jonathon. Preparation of 2-[5-[4-(2-morpholinoethoxy)phenyl]pyridin-2-yl]-N-benzylacetamide mesylate polymorph Form A with improved stability. U.S. Pat. Appl. Publ. (2009), 68pp., Cont.-in-part of U.S. Ser. No. 154,056. CODEN: USXXCO US 2009318450 A1 20091224 CAN 152:75049 AN 2009:1599300

3. Lau, Grace M.; Lau, Gillian M.; Yu, Guo-Liang; Gelman, Irwin H.; Gutowski, Alan; Hangauer, David; Fang, Jane W. S. Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro. Digestive Diseases and Sciences (2009), 54(7), 1465-1474. CODEN: DDSCDJ ISSN:0163-2116. AN 2009:677742

4. Hangauer, David G., Jr.; Coughlin, Daniel; Cody, Jeremy A.; Gale, Jonathan. Synthesis of [(morpholinoethoxy)phenyl]pyridine KX2-391 compositions for modulating a kinase cascade. U.S. Pat. Appl. Publ. (2008), 44 pp., Cont.-in-part of U.S. Ser. No. 5,792. CODEN: USXXCO US 2008287436 A1 20081120 CAN 149:556637 AN 2008:1398805

5. Hangauer, David G.; Coughlin, Daniel; Cody, Jeremy A.; Gale, Jonathan. Methods for preparing N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide [KX2-391] for use in modulating a kinase cascade. PCT Int. Appl. (2008), 94pp. CODEN: PIXXD2 WO 2008082637 A1 20080710 CAN 149:152968 AN 2008:831758